Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.

Feldmann M. et al, (2020), Lancet, 395, 1407 - 1409

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

Robinson PC. et al, (2020), The lancet rheumatology

Identification, preclinical profile, and clinical proof of concept of a novel palindromic orally bio-available pro-drug of miridesap

RICHARDS D. et al, (2019), British journal of pharmacology

Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study.

Deane AM. et al, (2018), Jpen j parenter enteral nutr, 42, 949 - 959

A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.

Marrinan SL. et al, (2018), Mov disord, 33, 329 - 332

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.

Richards DB. et al, (2018), Sci transl med, 10

Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy.

Babinsky VN. et al, (2017), Endocrinology, 158, 2486 - 2502

Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study.

Fernando D. et al, (2017), Ebiomedicine, 22, 249 - 255

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.

Hegade VS. et al, (2017), Lancet, 389, 1114 - 1123

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.

Ziauddeen H. et al, (2016), Neuropsychopharmacology, 41, 2647 - 2657

The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial.

Chapman MJ. et al, (2016), Crit care, 20

BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.

Hegade VS. et al, (2016), Bmc gastroenterol, 16

The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.

Hellström PM. et al, (2016), Br j pharmacol, 173, 1768 - 1777

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

Pepys MB. et al, (2015), Blood, 126

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.

Richards DB. et al, (2015), N engl j med, 373, 1106 - 1114

Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis

Sahota T. et al, (2015), Cpt: pharmacometrics & systems pharmacology, 4, 116 - 126

Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.

Ziauddeen H. et al, (2013), Mol psychiatry, 18, 1287 - 1293

The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects.

Ziauddeen H. et al, (2013), J clin pharmacol, 53, 1078 - 1090

Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.

Chamberlain SR. et al, (2012), Psychopharmacology (berl), 224, 501 - 509

Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.

Nathan PJ. et al, (2012), J clin pharmacol, 52, 1456 - 1467

Load More

Include forthcoming?